Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 1Papilloma 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1

Interventions

Cetuximab 6Cisplatin 4zalutumumab 3Radiotherapy 3Docetaxel 3Fluorouracil 2Carboplatin 2temsirolimus 1pembrolizumab 1osimertinib 1enzalutamide 1cobimetinib 1abemaciclib 1Taxes 1Sorafenib 1Risk Factors 1Radiation 1Papanicolaou Test 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Imatinib Mesylate 1Human Papillomavirus DNA Tests 1Gefitinib 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Colposcopy 1Cilengitide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Squamous Cell × Papanicolaou Test × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡